SES Extends Global Reach of Microsoft Azure ExpressRoute with Multi-orbit Satellite Systems
9.9.2019 09:55:00 EEST | Business Wire | Press release
SES today announced it will provide dedicated, private network connectivity from any vessel, airplane, enterprise, energy or government site in the world to Microsoft Azure via its unique multi-orbit satellite systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190908005042/en/
SES Extends Global Reach of Microsoft Azure ExpressRoute with Multi-orbit Satellite Systems (Photo: Business Wire)
As a partner of Azure ExpressRoute, SES will provide global reach and fibre-like high-performance to Azure customers via its complete portfolio of Geostationary Earth Orbit (GEO) satellites, Medium Earth Orbit (MEO) O3b constellation, global gateway network, and core terrestrial network infrastructure around the world. SES will offer Azure customers opportunities to leverage its satellite-enabled managed services to connect locations and sites in rural, remote and underserved locations, as well as vessels and airplanes out at sea and in the skies that previously did not have access to cloud services.
In addition to its global fleet of over 50 GEO satellites, SES also delivers managed data services over its proven O3b MEO satellite system, the only successful non-geostationary orbit (NGSO) broadband constellation. SES’s 20 O3b satellites comprise the only operational system today that can deliver fibre-equivalent, MEF-certified data connectivity services, and certified cloud connectivity services. The systems’ intelligent GEO- and MEO- orbit resilience that facilitate edge compute capabilities are key enablers in the seamless integration of high-performance satellite connectivity into Microsoft’s and their customers’ sites.
In addition, Azure customers also will be able to tap into SES’s groundbreaking next-generation MEO communications system, O3b mPOWER. Launching in 2021, O3b mPOWER will deliver ten times the throughput of the existing O3b constellation with unprecedented flexibility and dynamic control to help drive global cloud adoption everywhere.
“We believe that the economic and productivity benefits of the cloud should be easily available to all enterprise, maritime and aeronautical customers as well as government organisations, regardless of location. Now, as a Microsoft Azure ExpressRoute connectivity partner, we are expanding our strategic collaboration with Microsoft and extending intelligent cloud and edge services from Azure to the most underserved end points on the planet,” said JP Hemingway, CEO of SES Networks. “As the only satellite network services provider to operate a global, multi-orbit fleet utilising an extensive fleet of GEO and MEO satellites, SES stands ready to help Azure customers connect to any site at cloud scale, supporting critical enterprise workloads and offering an end-to-end network solution for emerging AI, IoT, video content services, and future applications to come.”
Ross Ortega, Partner, Product Manager of Azure Networking, Microsoft Corp. said, “We are collaborating with SES across a range of initiatives to build upon their expertise in satellite communications and increase connectivity to critical services and applications for customers in remote and underserved areas. This new collaboration between SES and Microsoft Azure Express Route further enables us to bring Azure to any business or government site.”
SES also announced today an expanded collaboration with Microsoft to benefit from Azure’s extensive cloud and AI capabilities to deliver one of the first broadcast-grade cloud services for media delivery. This builds on the broader strategic work between SES and Microsoft, as well as their shared common vision to reach everyone with intelligent cloud, media and network solutions.
More information on Azure ExpressRoute Data Sheet available here.
Follow us on:
Social Media
Blog
Media Library
About SES
SES is the world’s leading satellite operator with over 70 satellites in two different orbits, Geostationary Orbit (GEO) and Medium Earth Orbit (MEO). It provides a diverse range of customers with global video distribution and data connectivity services through two business units: SES Video and SES Networks. SES Video reaches over 355 million TV homes, through Direct-to-Home (DTH) platforms and cable, terrestrial, and IPTV networks globally. SES Video delivers a full suite of innovative end-to-end value-added services for both linear and digital distribution, and includes the ASTRA satellite system, which has the largest DTH television reach in Europe. SES Networks provides global managed data services, connecting people in a variety of sectors including telecommunications, maritime, aeronautical, and energy, as well as governments and institutions across the world. The SES Networks portfolio includes GovSat, a 50/50 public-private partnership between SES and the Luxembourg government, and O3b, the only non-geostationary system delivering fibre-like broadband services today. Further information is available at: www.ses.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190908005042/en/
Contact information
For further information:
Suzanne Ong
Public Relations
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom